Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) EBT (2020 - 2025)

Historic EBT for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to -$29.4 million.

  • Caribou Biosciences' EBT rose 2311.31% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year increase of 388.48%. This contributed to the annual value of -$149.1 million for FY2024, which is 4636.67% down from last year.
  • As of Q3 2025, Caribou Biosciences' EBT stood at -$29.4 million, which was up 2311.31% from -$47.6 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' EBT registered a high of -$13.2 million during Q1 2021, and its lowest value of -$47.6 million during Q2 2025.
  • For the 5-year period, Caribou Biosciences' EBT averaged around -$30.3 million, with its median value being -$30.6 million (2022).
  • Per our database at Business Quant, Caribou Biosciences' EBT plummeted by 64458.9% in 2021 and then surged by 4485.81% in 2023.
  • Caribou Biosciences' EBT (Quarter) stood at -$18.2 million in 2021, then tumbled by 68.4% to -$30.6 million in 2022, then fell by 22.45% to -$37.4 million in 2023, then dropped by 3.83% to -$38.9 million in 2024, then increased by 24.37% to -$29.4 million in 2025.
  • Its EBT stands at -$29.4 million for Q3 2025, versus -$47.6 million for Q2 2025 and -$42.9 million for Q1 2025.